

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q82517

Andrew Lennard LEWIS

Appln. No.: 10/501,393

Group Art Unit: 1618

Confirmation No.: 2458

Examiner: Blessing M. Fubara

Filed: January 13, 2005

For: POLYMER CONJUGATES

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. U.S. Patent No. 6,852,816 B2 issued February 8, 2005 to Lewis et al.
2. U.S. Patent No. 7,300,990 B2 issued November 27, 2007 to Lewis et al.
3. U.S. Patent No. 5,122,614 A issued June 16, 1992 to Zalipsky.
4. U.S. Patent No. 5,191,015 A issued March 2, 1993 to Sheppard et al.
5. U.S. Patent No. 5,198,493 A issued March 30, 1993 to Holmberg et al.
6. U.S. Patent No. 5,260,373 A issued November 9, 1993 to Profy et al.
7. U.S. Patent No. 5,328,955 A issued July 12, 1994 to Rhee et al.
8. U.S. Patent No. 5,444,150 A issued August 22, 1995 to Inman et al.
9. U.S. Patent No. 5,658,561 A issued August 19, 1997 to Nakabayashi et al.

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98  
U.S. Appln. No.: 10/501,393

Attorney Docket No.: Q82517

10. U.S. Patent No. 5,855,987 A issued January 5, 1999 to Margel et al.
11. U.S. Patent No. 5,932,462 A issued August 3, 1999 to Harris et al.
12. U.S. Patent No. 6,113,906 A issued September 5, 2000 to Greenwald et al.
13. U.S. Patent No. 6,251,382 B1 issued June 26, 2001 to Greenwald et al.
14. U.S. Patent No. 6,803,438 B1 issued October 12, 2004 to Brocchini et al.
15. U.S. Patent No. 6,828,029 B1 issued December 7, 2004 to Lewis et al.
16. U.S. Patent No. 6,833,276 B2 issued December 21, 2004 to Klaerner et al.
17. U.S. Patent No. 7,365,127 B2 issued April 29, 2008 to Wu et al.
18. U.S. Patent Publication No. 2005-02208801 A1 published June 10, 2005 to Lewis.
19. U.S. Patent Publication No. 2005-0163743 A1 published July 28, 2005 to Lewis.
20. U.S. Patent Publication No. 2006-0135714 A1 published June 22, 2006 to Lewis.
21. U.S. Patent Publication No. 2006-0069203 A1 published March 30, 2006 to Lewis.
22. U.S. Patent Publication No. 2002-0141965 A1 published October 3, 2002 to Ahn et al.
23. U.S. Patent Publication No. 2003-0158333 A1 published August 21, 2003 to Roberts et al.
24. U.S. Patent Publication No. 2004-0029794 A1 published February 12, 2004 to Veronese et al.
25. U.S. Patent Publication No. 2004-0030101 A1 published February 12, 2004 to Bailon et al.
26. U.S. Patent Publication No. 2004-0091451 A1 published May 13, 2004 to Charreyre et al.
27. U.S. Patent Publication No. 2004-0157276 A1 published August 12, 2004 to Sumida et al.
28. U.S. Patent Publication No. 2004-0162388 A1 published August 19, 2004 to Tjoeng.

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98  
U.S. Appln. No.: 10/501,393

Attorney Docket No.: Q82517

29. U.S. Patent Publication No. 2004-0235734 A1 published November 25, 2004 to Bossard et al.

30. U.S. Patent Publication No. 2005-0112203 A1 published May 26, 2005 to Shau et al.

31. U.S. Patent Publication No. 2007-0123646 A1 published May 31, 2007 to Lele et al.

32. U.S. Patent Publication No. 2007-0276088 A1 published November 29, 2007 to Maynard et al.

33. U.S. Patent Publication No. 2008-0206182 A1 published August 28, 2008 to Sommermeyer et al.

34. WO 93/01221 A, published January 21, 1993 to Biocompatibles Ltd.

35. WO 96/30421 A, published October 3, 1996 to Matyjaszewski.

36. WO 02/28929 A1, published April 11, 2002 to Biocompatibles Limited.

37. WO 02/100439 A1, published December 19, 2002 to Labopharm, Inc.

38. WO 03/062290 A1, published July 31, 2003 to Biocompatibles UK Limited.

39. WO 03/074026 A1, published September 12, 2003 to Biocompatibles UK Limited.

40. WO 03/074090 A2, published September 12, 2003 to Biocompatibles UK Limited.

41. E.J. Ashford et al, "First example of the atom transfer radical polymerization of an acidic monomer: direct synthesis of methacrylic acid copolymers in aqueous media", Chem. Commun., XP-002276944, 1999, pp. 1285-1286.

42. Monfardini et al., "A Branched Monomethoxypoly(ethylene glycol) for Protein Modification," Bioconjugate Chemistry, 1995, Vol. 6, No. 1, pp. 62-69.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. Patent No. 6,852,816, U.S. Patent No. 7,300,990, U.S. Patent No. 5,122,614, U.S. Patent No. 5,191,015, U.S. Patent No. 5,198,493, U.S. Patent No. 5,260,373, U.S. Patent No. 5,328,955,

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98  
U.S. Appln. No.: 10/501,393

Attorney Docket No.: Q82517

U.S. Patent No. 5,444,150, U.S. Patent No. 5,658,561, U.S. Patent No. 5,855,987, U.S. Patent No. 5,932,462, U.S. Patent No. 6,113,906, U.S. Patent No. 6,251,382, U.S. Patent No. 6,803,438, U.S. Patent No. 6,828,029, U.S. Patent No. 6,833,276, U.S. Patent No. 7,365,127, U.S. Patent Publication No. 2005-02208801, U.S. Patent Publication No. 2005-0163743, U.S. Patent Publication No. 2006-0135714, U.S. Patent Publication No. 2006-0069203, U.S. Patent Publication No. 2002-0141965, U.S. Patent Publication No. 2003-0158333, U.S. Patent Publication No. 2004-0029794, U.S. Patent Publication No. 2004-0030101, U.S. Patent Publication No. 2004-0091451, U.S. Patent Publication No. 2004-0157276, U.S. Patent Publication No. 2004-0162388, U.S. Patent Publication No. 2004-0235734, U.S. Patent Publication No. 2005-0112203, U.S. Patent Publication No. 2007-0123646, U.S. Patent Publication No. 2007-0276088, and U.S. Patent Publication No. 2008-0206182, respectively.

The present Information Disclosure Statement is being filed (without a Statement Under 37 C.F.R. § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and the statutory fee of \$180.00 under 37 C.F.R. § 1.17(p) is being submitted via the EFS Payment Screen.


The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98  
U.S. Appln. No.: 10/501,393

Attorney Docket No.: Q82517

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



---

Ryan C. Cady  
Registration No. 56,762

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: April 15, 2009